Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO - Get Free Report) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.26 and traded as low as $0.22. Northwest Biotherapeutics shares last traded at $0.24, with a volume of 2,985,060 shares traded.
Northwest Biotherapeutics Stock Up 2.4%
The firm's 50 day simple moving average is $0.25 and its 200 day simple moving average is $0.26. The company has a market cap of $372.07 million, a price-to-earnings ratio of -4.18 and a beta of -1.14.
Northwest Biotherapeutics (OTCMKTS:NWBO - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The biotechnology company reported ($0.01) EPS for the quarter. The company had revenue of $0.13 million for the quarter.
Northwest Biotherapeutics Company Profile
(
Get Free Report)
Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.
Recommended Stories
Before you consider Northwest Biotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Northwest Biotherapeutics wasn't on the list.
While Northwest Biotherapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
